EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial

Fjoralba Kristo, Flora Mazerolle, Thibaud Alin, Antoine Regnault, Justin Ferdinandus, Karolin Behringer, Janina Jablonski, Peter Borchmann, Ajibade Ashaye

Clinical Lymphoma Myeloma and Leukemia · 2026-06 · 26 (6) · 399-407.e4

DOI: 10.1016/j.clml.2026.03.011 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-06. Verfasst von Fjoralba Kristo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, MA, USA. Electronic address: Fjoralba.kristo@takeda.com. Hauptthemen laut MEDLINE: Hodgkin Disease, Peripheral Nervous System Diseases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Patient-reported outcome (PRO) data were analyzed to explore the experience of chemotherapy-induced peripheral neuropathy (CIPN) symptoms by patients with newly-diagnosed advanced-stage classic Hodgkin lymphoma (AS-cHL) treated with BrECADD versus eBEACOPP, and explore the association of CIPN symptoms with health-related quality of life (HRQoL). METHODS: Participants' experience was assessed during treatment and follow-up periods in a phase 3 trial of AS-cHL patients treated with BrECADD or eBEACOPP by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - core 30-item (QLQ-C30) questionnaire and the 20-item Chemotherapy-Induced Peripheral Neuropathy module (QLQ-CIPN20). Item responses were examined at each visit to describe the experience of CIPN symptoms per treatment arm. The association between patient-reported sensory symptoms and HRQoL was explored by describing PRO scores between participants with and without sensory symptoms. RESULTS: Sensory symptoms, the most frequent CIPN symptoms, tended to be reported by fewer participants in the BrECADD arm than the eBEACOPP arm, while their occurrence followed a similar pattern over time across arms: they were reported during the treatment period, before gradually decreasing post-treatment. Motor symptoms were less reported than sensory symptoms. Participants with sensory symptoms showed poorer overall health and physical function, as well asmore fatigue than those without. DISCUSSION: These exploratory PRO analyses highlight the occurrence of CIPN-related sensory symptoms, and to a lesser extent, motor symptoms, of AS-cHL patients treated with multiagent regimens. Treatments such as BrECADD may be associated with fewer CIPN sensory symptoms, which could prevent detrimental effects on patients' HRQoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseasePeripheral Nervous System DiseasesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleQuality of LifeMiddle AgedAdultPatient Reported Outcome MeasuresNeoplasm StagingAgedSurveys and Questionnaires

Stichwörter der Autor:innen

Chemotherapy-induced peripheral neuropathyHodgkin lymphomahealth-related quality of lifepatient-reported outcomesensory symptomstolerability

Autor:innen und Institutionen

  • Takeda Development Center Americas, Inc., Cambridge, MA, USA. Electronic address: Fjoralba.kristo@takeda.com.
  • Modus Outcomes, Lyon, France.
  • Department I of Internal Medicine, German Hodgkin Study Group (GHSG), Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Cologne, G…
  • Takeda Development Center Americas, Inc., Cambridge, MA, USA.

Zitieren

APA

Kristo, F., Mazerolle, F., Alin, T., Regnault, A., Ferdinandus, J., Behringer, K., Jablonski, J., Borchmann, P., & Ashaye, A. (2026). Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial. Clinical Lymphoma Myeloma and Leukemia, 26(6), 399-407.e4. https://doi.org/10.1016/j.clml.2026.03.011

Vancouver

Kristo F, Mazerolle F, Alin T, Regnault A, Ferdinandus J, Behringer K, et al. Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial. Clinical Lymphoma Myeloma and Leukemia. 2026;26(6):399-407.e4. doi:10.1016/j.clml.2026.03.011

BibTeX
@article{Kristo2026,
  author = {Kristo, Fjoralba and Mazerolle, Flora and Alin, Thibaud and Regnault, Antoine and Ferdinandus, Justin and Behringer, Karolin and Jablonski, Janina and Borchmann, Peter and Ashaye, Ajibade},
  title = {Patient Perspective on Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classic Hodgkin Lymphoma Treated With Multiagent Chemotherapy Regimens in the HD21 Trial},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {6},
  pages = {399--407.e4},
  doi = {10.1016/j.clml.2026.03.011}
}
Kostenlos starten →